Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI

Tessen HW, Hutzschenreuter U, Steffens CC, et al: The treatment of lung cancer in German outpatient centres. Data from a clinical registry-TLK Registry. Onkologie. 34:153. 2011.

Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI

Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS and Sata M: Metronomic chemotherapy: Possible clinical application in advanced hepatocellular carcinoma. Transl Oncol. 6:511–519. 2013. View Article : Google Scholar : PubMed/NCBI

Benzekry S, Pasquier E, Barbolosi D, Lacarelle B, Barlési F, André N and Ciccolini J: Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. Semin Cancer Biol. 35:53–61. 2015. View Article : Google Scholar : PubMed/NCBI

Weiss JM and Stinchcombe TE: Second-line therapy for advanced NSCLC. Oncologist. 18:947–953. 2013. View Article : Google Scholar : PubMed/NCBI

Zhang S, Liu J and Cheng Y: Metronomic chemotherapy-A new path to treat advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 18:232–239. 2015.(In Chinese). PubMed/NCBI

Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS and Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:1878–1886. 2000.PubMed/NCBI

Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P and Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 105:R15–R24. 2000. View Article : Google Scholar : PubMed/NCBI

Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, et al: Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 378:1079–1088. 2011. View Article : Google Scholar : PubMed/NCBI

Görn M, Habermann CR, Anige M, Thöm I, Schuch G, Andritzky B, Brandl S, Burkholder I, Edler L, Hossfeld DK, et al: A pilot study of docetaxel and trofosfamide as second-line ‘metronomic’ chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie. 31:185–189. 2008. View Article : Google Scholar : PubMed/NCBI

Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, Clark R and Mills GM: Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 21:2933–2939. 2003. View Article : Google Scholar : PubMed/NCBI

Schuette W, Blankenburg T, Guschall W, Dittrich I, Schroeder M, Schweisfurth H, Chemaissani A, Schumann C, Dickgreber N, Appel T and Ukena D: Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. Clin Lung Cancer. 7:338–343. 2006. View Article : Google Scholar : PubMed/NCBI

Biganzoli L, Lichtman S, Michel JP, Papamichael D, Quoix E, Walko C and Aapro M: Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG). Eur J Cancer. 51:2491–2500. 2015. View Article : Google Scholar : PubMed/NCBI

Camerini A, Banna GL, Cinieri S, Pezzuto A, Mencoboni M, Rosetti F, Figueiredo A, Rizzo P, Ricci A, Langenhoven L, et al: Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: A multicenter international retrospective analysis. Clin Transl Oncol. 21:790–795. 2019. View Article : Google Scholar : PubMed/NCBI

Camerini A, Valsuani C, Mazzoni F, Siclari O, Puccetti C, Donati S, Rondini M, Tartarelli G, Puccinelli P, Di Costanzo F and Amoroso D: Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status. Ann Oncol. 21:1290–1295. 2010. View Article : Google Scholar : PubMed/NCBI

Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, Lemarié E, Hartmann W, Novakova L, O'Brien M and Depierr A: A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol. 12:1375–1381. 2001. View Article : Google Scholar : PubMed/NCBI

Camerini A, Puccetti C, Donati S, Valsuani C, Petrella MC, Tartarelli G, Puccinelli P and Amoroso D: Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: Results of a phase II trial (MOVE trial). BMC Cancer. 15:3592015. View Article : Google Scholar : PubMed/NCBI

D'Ascanio M, Pezzuto A, Fiorentino C, Sposato B, Bruno P, Grieco A, Mancini R and Ricci A: Metronomic chemotherapy with vinorelbine produces clinical benefit and low toxicity in frail elderly patients affected by advanced non-small cell lung cancer. Biomed Res Int. 2018:62784032018.PubMed/NCBI

Pujol JL, Coffy A, Camerini A, Kotsakis A, Mencoboni M, Gusella M, Pasini F, Pezzuto A, Banna GL, Bilir C, et al: An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer. PLoS One. 14:e02209882019. View Article : Google Scholar : PubMed/NCBI

Pasini F, Barile C, Caruso D, Modena Y, Fraccon AP, Bertolaso L, Menon D, La Russa F, Crepaldi G, Bononi A, et al: Oral metronomic vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: Outcome and pharmacokinetics in the real world. Invest New Drugs. 36:927–932. 2018. View Article : Google Scholar : PubMed/NCBI

Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM and Beijnen JH: Taxanes: A new class of antitumor agents. Cancer Invest. 13:381–404. 1995. View Article : Google Scholar : PubMed/NCBI

Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, Debieuvre D, Pujol JL, Tredaniel J, Clouet P and Quoix E: Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 16:90–96. 2005. View Article : Google Scholar : PubMed/NCBI

Camps C, Massuti B, Jimenez A, Maestu I, Gómez RG, Isla D, González JL, Almenar D, Blasco A, Rosell R, et al: Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial. Ann Oncol. 17:467–472. 2006. View Article : Google Scholar : PubMed/NCBI

Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D and Georgoulias V: Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: A multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemother Pharmacol. 75:821–827. 2015. View Article : Google Scholar : PubMed/NCBI

Bozec A, Fischel JL and Milano G: Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. Curr Opin Oncol. 18:330–334. 2006. View Article : Google Scholar : PubMed/NCBI

Kontopodis E, Hatzidaki D, Varthalitis I, Kentepozidis N, Giassas S, Pantazopoulos N, Vardakis N, Rovithi M, Georgoulias V and Agelaki S: A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): A phase II study of the Hellenic Oncology Research Group. J Chemotherapy. 25:49–55. 2013. View Article : Google Scholar

Hainsworth JD, Burris HA III, Litchy S, Morrissey LH, Barton JH, Bradof JE and Greco FA: Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer. 89:328–333. 2000. View Article : Google Scholar : PubMed/NCBI

Noronha V, Patil VM, Joshi A and Prabhash K: Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer. Indian J Cancer. 50:122–127. 2013. View Article : Google Scholar : PubMed/NCBI

Kouroussis C, Vamvakas L, Vardakis N, Kotsakis A, Kalykaki A, Kalbakis K, Saridaki Z, Kentepozidis N, Giassas S and Georgoulias V: Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: A phase II study. Oncology. 76:112–117. 2009. View Article : Google Scholar : PubMed/NCBI

Dziadziuszko R, Ardizzoni A, Postmus PE, Smit EF, Price A, Debruyne C, Legrand C and Giaccone G; EORTC Lung Cancer Group, : Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases: A phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer. 39:1271–1276. 2003. View Article : Google Scholar : PubMed/NCBI

Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La Placa M, Sciandivasci A, Paolelli L, Pascucci A, Rossi M, et al: A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep. 16:133–140. 2006.PubMed/NCBI

Hirsch FR, Suda K, Wiens J and Bunn PA Jr: New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI

Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol. 22:777–784. 2004. View Article : Google Scholar : PubMed/NCBI

Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI

Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 23:5892–5899. 2005. View Article : Google Scholar : PubMed/NCBI

Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 25:1545–1552. 2007. View Article : Google Scholar : PubMed/NCBI

Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 4:423–436. 2004. View Article : Google Scholar : PubMed/NCBI

Chen YM, Fan WC, Tsai CM, Liu SH, Shih JF, Chou TY, Wu CH, Chou KT, Lee YC, Perng RP, et al: A Phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. J Thorac Oncol. 6:1110–1116. 2011. View Article : Google Scholar : PubMed/NCBI

Sutiman N, Zhang ZX, Tan EH, Ang MK, Tan SW, Toh CK, Ng QS, Chowbay B and Lim WT: Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules. PLoS One. 11:e01543162016. View Article : Google Scholar : PubMed/NCBI

Gusella M, Pasini F, Caruso D, Barile C, Modena Y, Fraccon AP, Bertolaso L, Menon D, Crepaldi G, Bononi A, et al: Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: Correlations with pharmacokinetics and MDR1 polymorphisms. Cancer Chemother Pharmacol. 83:493–500. 2019. View Article : Google Scholar : PubMed/NCBI

Orlandi P, Di Desidero T, Salvia G, Muscatello B, Francia G and Bocci G: Metronomic vinorelbine is directly active on non small cell lung cancer cells and sensitizes the EGFR(L858R/T790M) cells to reversible EGFR tyrosine kinase inhibitors. Biochem Pharmacol. 152:327–337. 2018. View Article : Google Scholar : PubMed/NCBI

Qin RS, Zhang ZH, Zhu NP, Chen F, Guo Q, Hu HW, Fu SZ, Liu SS, Chen Y, Fan J and Han YW: Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma. BMC Cancer. 18:9672018. View Article : Google Scholar : PubMed/NCBI

Wang R, Qin S, Chen Y, Li Y, Chen C, Wang Z, Zheng R and Wu Q: Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer. Oncol Rep. 28:439–445. 2012. View Article : Google Scholar : PubMed/NCBI

Tan EH, Tan DS, Li WY, Haaland B, Ang MK, Chau NM, Toh CK, Tan IB, Koh TS, Thng CH, et al: Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. Lung Cancer. 88:289–296. 2015. View Article : Google Scholar : PubMed/NCBI

Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, et al: Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther. 9:685–693. 2010. View Article : Google Scholar : PubMed/NCBI

Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, et al: Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol Ther. 12:112–118. 2011. View Article : Google Scholar : PubMed/NCBI

Marquette CL, Grant SC, DeShazo M, Reddy V, Cantor A, MileyMary Jerome D and Robert F: Phase II study of metronomic chemotherapy (MC) with bevacizumab (B) in patients (Pts) with advanced (Adv) nonsquamous non-small cell lung cancer (NS-NSCLC). J Clin Oncol. 31 (15 Suppl):S80572013. View Article : Google Scholar

Revannasiddaiah S and Susheela SP: Chemically enhanced radiotherapy: Visions for the future. Ann Transl Med. 4:522016.PubMed/NCBI

Revannasiddaiah S, Joshi SC, Pandey KC, Rastogi M, Sharma M and Gupta M: The results with the addition of metronomic cyclophosphamide to palliative radiotherapy for the treatment of non-small cell lung carcinoma. Ann Transl Med. 3:3052015.PubMed/NCBI

Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, et al: Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). Oncotarget. 8:75904–75913. 2017. View Article : Google Scholar : PubMed/NCBI

Moserle L, Amadori A and Indraccolo S: The angiogenic Switch: Implications in the regulation of tumor dormancy. Curr Mol Med. 9:935–941. 2009. View Article : Google Scholar : PubMed/NCBI

Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar : PubMed/NCBI

Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, et al: Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther. 9:685–693. 2010. View Article : Google Scholar : PubMed/NCBI

Shaikh AJ and Masood N: Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: A case report. J Med Case Rep. 4:2742010. View Article : Google Scholar : PubMed/NCBI

Le Deley MC, Leblanc T, Shamsaldin A, Raquin MA, Lacour B, Sommelet D, Chompret A, Cayuela JM, Bayle C, Bernheim A, et al: Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 21:1074–1081. 2003. View Article : Google Scholar : PubMed/NCBI

Vergnenegre A, Monnet I, Bizieux A, Bernardi M, Chiapa AM, Léna H, Chouaïd C and Robinet G: Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer-VinMetAtezo trial, (GFPC^‡ 04–2017). Future Oncol. 16:5–10. 2020. View Article : Google Scholar : PubMed/NCBI

Platania M, Pasini F, Porcu L, Boeri M, Verderame F, Modena Y, Del Conte A, Nichetti F, Garassino MC, Martinetti A, et al: Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. Lung Cancer. 132:17–23. 2019. View Article : Google Scholar : PubMed/NCBI

Munzone E and Colleoni M: Clinical overview of metronomic chemotherapy in breast cancer. Nat Rev Clin Oncol. 12:631–644. 2015. View Article : Google Scholar : PubMed/NCBI

de Castro G, Puglisi F, de Azambuja E, El Saghir NS and Awada A: Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the ‘do ut des’ paradigm). Crit Rev Oncol Hemat. 59:40–50. 2006. View Article : Google Scholar

Kerbel RS: A decade of experience in developing preclinical models of advanced- or Early-stage spontaneous metastasis to study antiangiogenic drugs, metronomic chemotherapy, and the tumor microenvironment. Cancer J. 21:274–283. 2015. View Article : Google Scholar : PubMed/NCBI

Maiti R: Metronomic chemotherapy. J Pharmacol Pharmacother. 5:186–192. 2014. View Article : Google Scholar : PubMed/NCBI

Bocci G, Nicolaou KC and Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62:6938–6943. 2002.PubMed/NCBI

Grant DS, Williams TL, Zahaczewsky M and Dicker AP: Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer. 104:121–129. 2003. View Article : Google Scholar : PubMed/NCBI

Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y and Kerbel RS: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63:4342–4346. 2003.PubMed/NCBI

Mpekris F, Baish JW, Stylianopoulos T and Jain RK: Role of vascular normalization in benefit from metronomic chemotherapy. Proc Natl Acad Sci USA. 114:1994–1999. 2017. View Article : Google Scholar : PubMed/NCBI

Sarmiento R and Gasparini G: Antiangiogenic metronomic chemotherapy. Onkologie. 31:161–162. 2008. View Article : Google Scholar : PubMed/NCBI

Laquente B, Vinals F and Germa JR: Metronomic chemotherapy: An antiangiogenic scheduling. Clin Transl Oncol. 9:93–98. 2007. View Article : Google Scholar : PubMed/NCBI

Pasquier E, Kavallaris M and Andre N: Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol. 7:455–465. 2010. View Article : Google Scholar : PubMed/NCBI

Andre N, Carre M and Pasquier E: Metronomics: Towards personalized chemotherapy? Nat Rev Clin Oncol. 11:413–431. 2014. View Article : Google Scholar : PubMed/NCBI

Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L and Chauffert B: Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 56:641–648. 2007. View Article : Google Scholar : PubMed/NCBI

Shaked Y, Pham E, Hariharan S, Magidey K, Beyar-Katz O, Xu P, Man S, Wu FT, Miller V, Andrews D and Kerbel RS: Evidence Implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy. Cancer Res. 76:5983–5993. 2016. View Article : Google Scholar : PubMed/NCBI

Kosmaczewska A, Ciszak L, Potoczek S and Frydecka I: The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp (Warsz). 56:181–191. 2008. View Article : Google Scholar : PubMed/NCBI

Hao YB, Yi SY, Ruan J, Zhao L and Nan KJ: New insights into metronomic chemotherapy-induced immunoregulation. Cancer Lett. 354:220–226. 2014. View Article : Google Scholar : PubMed/NCBI

Banissi C, Ghiringhelli F, Chen L and Carpentier AF: Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother. 58:1627–1634. 2009. View Article : Google Scholar : PubMed/NCBI

Ghiringhelli F, Ménard C, Martin F and Zitvogel L: The role of regulatory T cells in the control of natural killer cells: Relevance during tumor progression. Immunol Rev. 214:229–238. 2006. View Article : Google Scholar : PubMed/NCBI

Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S and Djeu JY: A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 16:4583–4594. 2010. View Article : Google Scholar : PubMed/NCBI

Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, Shurin GV, Shurin MR and Umansky V: Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol. 190:2464–2471. 2013. View Article : Google Scholar : PubMed/NCBI

Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. 2010. View Article : Google Scholar : PubMed/NCBI

Bracci L, Schiavoni G, Sistigu A and Belardelli F: Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21:15–25. 2014. View Article : Google Scholar : PubMed/NCBI

Kareva I, Waxman DJ and Lakka Klement G: Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 358:100–106. 2015. View Article : Google Scholar : PubMed/NCBI

Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F and Calvo A: Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest. 92:952–966. 2012. View Article : Google Scholar : PubMed/NCBI

Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ and Kerbel RS: Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 67:3560–3564. 2007. View Article : Google Scholar : PubMed/NCBI

Vives M, Ginesta MM, Gracova K, Graupera M, Casanovas O, Capellà G, Serrano T, Laquente B and Viñals F: Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. Int J Cancer. 133:2464–2472. 2013. View Article : Google Scholar : PubMed/NCBI

Yan H, Chen X, Zhang QP, Qin J, Li H, Liu C, Calhoun-Davis T, Coletta LD, Klostergaard J, Fokt I, et al: Drug-tolerant cancer cells show reduced tumor-initiating capacity: Depletion of CD44(+) cells and evidence for epigenetic mechanisms. PLoS One. 6:e243972011. View Article : Google Scholar : PubMed/NCBI

Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846. 2007. View Article : Google Scholar : PubMed/NCBI

Udagawa T: Tumor dormancy of primary and secondary cancers. Apmis. 116:615–628. 2008. View Article : Google Scholar : PubMed/NCBI

Natale G and Bocci G: Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data. Cancer Lett. 432:28–37. 2018. View Article : Google Scholar : PubMed/NCBI

Schirrmacher V: T-cell immunity in the induction and maintenance of a tumour dormant state. Semin Cancer Biol. 11:285–295. 2001. View Article : Google Scholar : PubMed/NCBI

Weir G, Hrytsenko O, Stanford M, Karkada M, Berinstein N and Mansour M: Abstract 2508: Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and anti-PD1 monoclonal antibody provides effective control of tumors in multiple models. Cancer Res. 752015.doi: 10.1158/1538-7445.AM2015-2508.

Rajasekaran T, Ng QS, Tan DS, Lim WT, Ang MK, Toh CK, Chowbay B, Kanesvaran R and Tan EH: Metronomic chemotherapy: A relook at its basis and rationale. Cancer Lett. 388:328–333. 2017. View Article : Google Scholar : PubMed/NCBI

Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, Werner A, Bohnenkamp H, Guenzi E, Preissler G, Michaelis U, et al: Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer. 126:1235–1245. 2010. View Article : Google Scholar : PubMed/NCBI

Panigrahy D, Kaipainen A, Butterfield CE, Chaponis DM, Laforme AM, Folkman J and Kieran MW: Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med. 1:739–746. 2010. View Article : Google Scholar : PubMed/NCBI

Jones BS, Jerome MS, Miley D, Jackson BE, DeShazo MR, Reddy VV, Singh KP, Brown OC and Robert F: Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 106:125–130. 2017. View Article : Google Scholar : PubMed/NCBI

Giorgio CG, Giuffrida D, Pappalardo A, Russo A, Santini D, Salice P, Blanco G, Castorina S, Failla G and Bordonaro R: Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: Phase II study. Lung Cancer. 50:247–254. 2005. View Article : Google Scholar : PubMed/NCBI

Banna GL, Camerini A, Bronte G, Anile G, Addeo A, Rundo F, Zanghì G, Lal R and Libra M: Oral metronomic vinorelbine in advanced non-small cell lung cancer patients unfit for chemotherapy. Anticancer Res. 38:3689–3697. 2018. View Article : Google Scholar : PubMed/NCBI

Bilir C, Durak S, Kizilkaya B, Hacibekiroglu I, Nayir E and Engin H: Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status. Curr Oncol. 24:e199–e204. 2017. View Article : Google Scholar : PubMed/NCBI

Mencoboni M, Filiberti RA, Taveggia P, Del Corso L, Del Conte A, Covesnon MG, Puccetti C, Donati S, Auriati L, Amoroso D and Camerini A: Safety of first-line chemotherapy with metronomic single-agent oral vinorelbine in elderly patients with NSCLC. Anticancer Res. 37:3189–3194. 2017.PubMed/NCBI